Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma.
The drugs involved in this study are:
- Pembrolizumab (Keytruda)
- Trametinib (Mekinist)
- Dabrafenib (Tafinlar)
A phase II trial of abbreviated MAPK targeted therapy plus pembrolizumab in patients with unresectable or metastatic melanoma
- ClinicalTrials.gov Identifier: NCT03149029
- Protocol Number: 16-642
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required